Graft Versus Host Disease Market Expected to rise, 2034 | Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio

The Graft Versus Host Disease market growth is driven by factors like increase in the prevalence of Graft Versus Host Disease, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Graft Versus Host Disease market report [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Graft Versus Host Disease market size, share, Graft Versus Host Disease epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Graft Versus Host Disease market size growth forward.

Some of the key highlights from the Graft Versus Host Disease Market Insights Report:

*
In December 2024, the FDA approved Mesoblast's cell therapy, Ryoncil, for the treatment of Graft Versus Host Disease (GVHD) in patients who have undergone stem cell or bone marrow transplants. Ryoncil is the first mesenchymal stromal cell therapy authorized for pediatric patients aged two months and older whose GVHD symptoms have not responded to standard steroid therapy.

*
On August 14, 2024, the FDA granted approval to AstraZeneca's IMFINZI (durvalumab) for treating adult patients with resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) who do not have known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. The approved treatment regimen includes IMFINZI in combination with neoadjuvant chemotherapy before surgery, followed by IMFINZI as adjuvant monotherapy after surgery.

*
The graft versus host disease companies are Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others.

*
The graft versus host disease therapies are JAKAFI MOA/JAKAVI (ruxolitinib), IMBRUVICA (ibrutinib), ZEMAIRA (CSL 964, alpha-1 antitrypsin), EQ001 (itolizumab; Bmab600), and others.

*
The Graft Versus Host Disease (GVHD) Treatment Market is expected to experience steady growth, with a strong compound annual growth rate (CAGR) projected from 2025 to 2034. This expansion across the seven major markets (7MM) will be driven by the introduction of novel therapies, including ZEMAIRA, EQ001, MaaT013, and RGI-2001, among others.

*
According to DelveInsight's analysis, the GVHD market in the 7MM was valued at approximately USD 1,301.8 million in 2023. Over the forecast period (2025-2034), the market is anticipated to grow at a CAGR of 8.2%.

*
Currently, available GVHD treatments include steroids, NIKTIMVO, JAKAVI/JAKAFI MOA, IMBRUVICA, RYONCIL/TEMCELL HS, and ORENCIA, among others. Meanwhile, pharmaceutical companies such as CSL Behring, Equillium, MaaT Pharma, and REGiMMUNE are actively advancing their pipeline therapies through various clinical trial phases, fostering innovation and creating substantial growth opportunities.

*
In 2023, approximately 52,000 cases of GVHD were reported across the 7MM. Of these, the United States accounted for 45%, the EU4 and the UK made up nearly 39%, and Japan represented 16% of the cases.

*
A significant development occurred in November 2024, when Equillium expedited the Phase III EQUATOR study timeline for EQ001, targeting GVHD, with completion now expected in Q1 2025.

*
As per DelveInsight analysis, the Graft Versus Host Disease market is anticipated to witness growth at a considerable CAGR

Strategise your business goals by understanding market dynamics @ Graft Versus Host Disease Market Landscape [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Graft Versus Host Disease Overview

Graft Versus Host Disease (GVHD) is an immune-related complication that arises following transplant procedures, occurring when donor-derived immune cells (T cells) attack the recipient's healthy tissues. This condition is a common side effect of allogeneic bone marrow transplants and, in some cases, can be life-threatening. Before undergoing an allogeneic stem cell transplant, patients typically receive high-dose chemotherapy or radiation to eliminate diseased cells and prepare the body for donor cell engraftment.

There are two main types of GVHD: acute and chronic. Recipients of allogeneic transplants may develop either form, both, or none at all. On average, 30-50% of patients undergoing allogeneic hematopoietic cell transplantation experience GVHD.

Diagnosis of GVHD is based on clinical evaluation, organ biopsies (skin, liver, gastrointestinal tract), and ruling out conditions with similar presentations, such as infections or drug reactions. While laboratory tests and imaging can assist in assessment, a major challenge remains the lack of predictive biomarkers to identify at-risk patients before symptoms arise. Diagnosis requires at least one characteristic clinical manifestation (e.g., lichenoid lesions or scleroderma) after excluding alternative causes. Emerging blood-based biomarker panels hold promise for improving risk stratification and guiding personalized immunosuppressive therapy, addressing current limitations in GVHD diagnosis.

Do you know the treatment paradigms for different countries? Download our Graft Versus Host Disease Market Sample Report [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Graft Versus Host Disease Epidemiology Insights

*
According to DelveInsight's epidemiology model, approximately 57,000 allogeneic transplant cases and nearly 52,000 cases of Graft Versus Host Disease (GVHD) were recorded across the seven major markets (7MM) in 2023, with numbers projected to increase by 2034.

*
The United States had the highest prevalence of GVHD among the 7MM, reporting around 24,000 cases in 2023, a figure anticipated to grow further by 2034.

Graft Versus Host Disease Epidemiology Segmentation

DelveInsight's Graft Versus Host Disease market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Graft Versus Host Disease historical patient pools and forecasted Graft Versus Host Disease patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Graft Versus Host Disease Market report proffers epidemiological analysis for the study period 2020-34 in the 7MM segmented into:

*
Graft Versus Host Disease Prevalence

*
Age-Specific Graft Versus Host Disease Prevalence

*
Gender-Specific Graft Versus Host Disease Prevalence

*
Diagnosed and Treatable Cases of Graft Versus Host Disease

Visit for more @ Graft Versus Host Disease Epidemiological Insights [https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Graft Versus Host Disease Treatment Market

Graft Versus Host Disease (GVHD) is a significant complication of allogeneic stem cell transplantation, where stem cells are derived from bone marrow, peripheral blood, or umbilical cord blood. The primary first-line treatment involves corticosteroids such as prednisone and methylprednisolone, often used in combination with other immunosuppressive agents.

Mild GVHD is typically managed with topical steroids, while systemic cases necessitate stronger immunosuppressive therapies. Treatment is tailored to the severity of the disease, with localized symptoms addressed using topical treatments, whereas more severe cases require systemic corticosteroids like prednisone to control the immune response.

Graft Versus Host Disease Market Outlook

Graft Versus Host Disease (GVHD) is a significant complication of allogeneic stem cell transplants. The primary first-line treatment involves corticosteroids such as prednisone, often used in combination with immunosuppressants like cyclosporine.

Mild GVHD can typically be managed with topical steroids, while more severe cases require systemic corticosteroids. Prednisone is the preferred treatment for widespread symptoms, whereas localized therapies-such as steroid creams or eye drops-are used for mild, organ-specific cases.

Several pharmaceutical companies are actively developing treatments for Graft Versus Host Disease (GVHD). Notable companies include CSL, with ZEMAIRA (CSL964, Alpha-1 antitrypsin), Equillium Bio, developing EQ001 (Itolizumab), MaaT Pharma, working on MaaT013, and Medac, advancing MC0518, among others.

In addition, multiple GVHD therapies are currently in the early stages of development, including:

*
RLS-0071 by ReAlta Life Sciences

*
Vimseltinib by Deciphera Pharmaceuticals

*
ASC-930 by ASC Therapeutics

*
RGI-2001 by REGiMMUNE

*
CYP-001 by Cynata Therapeutics

*
Arsenic trioxide (AsO) by BioSenic (Medsenic)

*
TRX103 (Tregs) by Tr1X

*
TCD601 (Siplizumab) by ITB-MED

*
F-652 by Evive Biotech

*
RHPRG4 by Lubris BioPharma

*
XBI302 by Xbiome

*
RG6287 by Genentech

*
ALTB-168 by AltruBio

*
SER-155 by Seres Therapeutics

These emerging treatments represent ongoing efforts to improve GVHD management and expand therapeutic options.

Graft Versus Host Disease Marketed Therapies

*
JAKAFI MOA/JAKAVI (ruxolitinib): Incyte

*
IMBRUVICA (ibrutinib): Pharmacyclics (acquired by AbbVie)/ Janssen

Graft Versus Host Disease Emerging Therapies

*
ZEMAIRA (CSL 964, alpha-1 antitrypsin): CSL Behring

*
EQ001 (itolizumab; Bmab600): Equillium/Biocon

Graft Versus Host Disease Key Companies

*
Biocon, medac GmbH, MaaT Pharma, ElsaLys Biotech, Glia, Syndax Pharmaceuticals, ASC Therapeutics, SCM Lifescience, REGiMMUNE, Roche, VectivBio, Chia Tai Tianqing Pharmaceutical Group, Amgen, Pfizer, Plexxikon, Medsenic, Xenothera, and others

For more information, visit Graft Versus Host Disease Market Analysis, Patient Pool, and Emerging Therapies [https://www.delveinsight.com/report-store/graft-versus-host-disease-gvhd-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Scope of the Graft Versus Host Disease Market Report:

*
11 Years Forecast

*
7MM Coverage

*
Descriptive overview of Graft Versus Host Disease, causes, signs and symptoms, diagnosis, treatment

*
Comprehensive insight into Graft Versus Host Disease epidemiology in the 7MM

*
Graft Versus Host Disease marketed and emerging therapies

*
Graft Versus Host Disease companies

*
Graft Versus Host Disease market drivers and barriers

Table of Contents:

1 Graft Versus Host Disease Market Key Comprehensive Insights

2 Graft Versus Host Disease Market Report Introduction

3 Competitive Intelligence Analysis for Graft Versus Host Disease

4 Graft Versus Host Disease Market Analysis Overview at a Glance

5 Executive Summary of Graft Versus Host Disease

6 Graft Versus Host Disease Epidemiology and Market Methodology

7 Graft Versus Host Disease Epidemiology and Patient Population

8 Graft Versus Host Disease Patient Journey

9 Graft Versus Host Disease Treatment Algorithm, Graft Versus Host Disease Current Treatment, and Medical Practices

10 Key Endpoints in Graft Versus Host Disease Clinical Trials

11 Graft Versus Host Disease Marketed Therapies

12 Graft Versus Host Disease Emerging Therapies

13 Graft Versus Host Disease: 7 Major Market Analysis

14 Attribute analysis

15 Access and Reimbursement Overview of Graft Versus Host Disease

16 Graft Versus Host Disease Market Key Opinion Leaders Reviews

18 Graft Versus Host Disease Market Drivers

19 Graft Versus Host Disease Market Barriers

20 SWOT Analysis

21 Disclaimer

22 DelveInsight Capabilities

23 About DelveInsight

Related Reports:

Graft Versus Host Disease Epidemiology 2034

DelveInsight's "Graft Versus Host Disease - Epidemiology Forecast to 2034" report delivers an in-depth understanding of the disease, historical and forecasted Graft Versus Host Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Graft Versus Host Disease Pipeline 2024

"Graft Versus Host Disease Pipeline Insights, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Graft Versus Host Disease market. A detailed picture of the Graft Versus Host Disease pipeline landscape is provided, which includes the disease overview and Graft Versus Host Disease treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=graft-versus-host-disease-market-expected-to-rise-2034-biocon-medac-gmbh-maat-pharma-elsalys-biotech-glia-syndax-pharmaceuticals-asc-therapeutics-scm-lifescience-regimmune-roche-vectivbio]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.